Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
PHASE3
The purpose of this study is to assess the efficacy and safety of the combi...
Status
Completed
Location
University of South Alabama, Mitchell Cancer Institute ( Site 0065)
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
PHASE2
The primary scientific question of interest of this study is whether the co...
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
PHASE3
The safety and efficacy of pembrolizumab plus the investigator's choice of ...
Status
Active Not Recruiting
Location
University of Alabama at Birmingham-Medicine ( Site 0065)
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
PHASE3
This is a study to assess the efficacy and safety of pembrolizumab (MK-3475...